source
- Capricor boosts manufacturing capacity as FDA decision on DMD cell therapy loomsCapricor Therapeutics, a biotech developing a cell therapy for Duchenne muscular dystrophy, is preparing for an FDA decision expected by late November. The company’s third-quarter operating expens…
- PepGen stock surges as DM1 oligonucleotide PGN-EDODM1 shows record splicing correction in Phase 2PepGen reported that its experimental oligonucleotide PGN-EDODM1 achieved a mean splicing correction of 46.5% at week 13 in a Phase 2 trial for myotonic dystrophy type 1 (DM1). This performance exc…